Pharmaceutical Technology

MAY 24, 2023

Y-mAbs Therapeutics has received marketing authorisation for Danyelza (naxitamab-gqgk) 40mg/10mL injection from the Brazilian Health Regulatory Agency, Agência Nacional de Vigilância Sanitária, to treat high-risk neuroblastoma. The therapy is given three times a week and repeated every four weeks.

Marketing 130

Marketing Licensing Licensing Antibody 130

Pharmaceutical Technology

MAY 10, 2023

According to the US government, Gilead had repeatedly refused to license patents related to PrEP research undertaken by the Department of Health and Human Services’ (HHS) Centers for Disease Control and Prevention (CDC). This research dates to the mid-2000s when CDC scientists developed the PrEP regimen, argued the government.

Drugs 264

Drugs FDA Approval Containment Licensing 264

BioPharma Reporter

MAY 6, 2021

Moderna has reported the first profitable quarter in the companyâs history: after 10 years of research and several billion dollars of investment in its mRNA platform. The next step will be to start a rolling submission for a Biologics License Application (BLA) for its COVID-19 vaccine with the FDA this month.

Licensing 94

Licensing Licensing Vaccine Vaccination 94

Pharmaceutical Technology

JUNE 19, 2023

Indian pharmaceutical company Laurus Labs has signed a memorandum of agreement (MoA) with the Indian Institute of Technology, Kanpur (IIT Kanpur) to bring new gene therapy products to the market. Laurus Labs will be responsible for launching these products in India and emerging markets.

Gene Therapy 246

Gene Therapy Gene Production Pharma Companies 246

Pharmaceutical Technology

OCTOBER 25, 2022

There are options in the future to possibly apply the worldwide research and development (R&D), manufacturing and marketing expertise of Astellas in gene therapy to AAV gene therapy development programmes of Taysha for genetic ailments of the central nervous system (CNS).

Gene Therapy 264

Gene Therapy Gene Development Genetics 264

World of DTC Marketing

MAY 24, 2022

DEA agents interviewed former Cerebral employees about clinician licensing issues and allegations that some patients had set up multiple accounts to obtain more drugs, Insider reported , citing sources. And the COVID-19 pandemic has likely given the market an added boost, Torous adds.

Licensing 252

Licensing Licensing Scientist Production 252

Pharmaceutical Technology

AUGUST 10, 2022

Cerevance has entered a multi-year strategic research partnership with Merck (MSD outside North America) to discover new targets for Alzheimer’s disease. Furthermore, Cerevance will simultaneously out-license a discovery-stage programme to Merck under the partnership. “We

Licensing 223

Licensing Licensing Sales Development 223

Cloudbyz

NOVEMBER 22, 2024

This prestigious acknowledgment places Cloudbyz among the top-performing companies globally, known for delivering scalable and intuitive CTMS solutions that empower clinical research teams. Selected extracts from Everest Group’s PEAK Matrix® reports do not necessarily provide the full context of our research and analysis. 

Life Science 52

Life Science Clinical Trials Clinical Trials Compliance 52

Pharmaceutical Technology

JANUARY 5, 2023

It will also have the potential for receiving research and development (R&D) and commercial milestones of up to $685m, along with tiered royalties. Additionally, Capsida can take part in development and marketing in the US for one of the collaboration programmes in return for a gross margin share in it.

Gene Therapy 237

Gene Therapy Gene Development Engineer 237

Cloudbyz

AUGUST 2, 2022

Premarketing drug studies vs Post- Marketing research Premarketing drug studies consist of phase I-III trials, and are represented by pharmacokinetic and pharmacodynamic studies, dose ranging studies, and Randomized Controlled Trials (RCTs). Approximately only 20 % of the drugs that enter phase I are approved for marketing.

Marketing 52

Marketing Research Trials Clinical Trials 52

pharmaphorum

SEPTEMBER 29, 2020

The industry is asking itself how to stay innovative, how to develop and bring to market higher quality therapies to patients – and how to do this faster and more efficiently. A diversity of collaboration types.

Research 132

Research Gene Editing Development Gene 132

Pharmaceutical Technology

AUGUST 1, 2022

As a result, multiple vaccines, including Pfizer /BioNTech’s mRNA vaccine, Comirnaty, were licensed for use within a year of development beginning. Many new therapeutics are needed to treat the broad range of bacterial infections, and bringing new antibiotics to market is both difficult and expensive.

Vaccination 234

Vaccination Vaccine Bacteria Life Science 234

Pharmaceutical Technology

DECEMBER 26, 2022

LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). Till date, the company has signed a total of 12 ADC licensing deals, worth more than $5bn.

Antibody 130

Antibody Development Drugs Licensing 130

Pharmaceutical Technology

FEBRUARY 9, 2023

ReviR Therapeutics has signed a research collaboration and option-to-license agreement with Asieris Pharmaceuticals to discover new oncology therapeutics. Asieris Pharmaceuticals discovers, develops, and markets advanced therapeutics to treat GU tumours and other related diseases.

Development 241

Development RNA Gene Therapy Genetics 241

Pharmaceutical Technology

AUGUST 2, 2022

Sosei Heptares , a corporate brand of Sosei Group Corporation, has signed a new drug discovery partnership and option-to-license agreement with AbbVie for discovering, developing and marketing new therapies for neurological ailments. Additionally, AbbVie will make tiered royalty payments based on global product sales to Sosei Heptares.

Development 147

Development Licensing Licensing Branding 147

pharmaphorum

JANUARY 4, 2023

The Janssen Pharmaceutical Companies of Johnson & Johnson have submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA), seeking approval of talquetamab for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). This reduces the timeframe for the MAA to be reviewed.

Marketing 98

Marketing Antibody Medicine FDA Approval 98

Pharmaceutical Technology

FEBRUARY 26, 2023

Coupled with this, the harsh conditions of the biotech market affected some companies. Regulatory concerns remain Overall, microbiome research has not advanced as much as expected, which is partly due to safety issues, says Hota. It will take some time for research to thaw,” she adds.

Bacteria 278

Bacteria Trials Research Medicine 278

Pfizer

JANUARY 27, 2023

Pfizer Responds to Research Claims carterda Fri, 01/27/2023 - 19:48 Pfizer Responds to Research Claims Friday, January 27, 2023 - 08:00pm Share New York, N.Y., In the ongoing development of the Pfizer-BioNTech COVID-19 vaccine, Pfizer has not conducted gain of function or directed evolution research.

Research 112

Research Vaccine Vaccination Drugs 112

Delveinsight

AUGUST 23, 2021

The present treatment approach in the Von Hippel-Lindau therapy market revolves around controlling and preservation of functional parenchyma to avoid the morbidity associated with renal or adrenal loss. by 2030 Owing to Increasing Prevalence and Emerging Therapieswth of the VHL disease pipeline market and influx of key pharma companies.

Marketing 98

Marketing Clinical Trials Clinical Trials Trials 98

XTalks

MARCH 7, 2025

While National Kidney Month drives domestic initiatives in research, prevention and patient care, World Kidney Day broadens this commitment by sharing success stories and innovative screening campaigns from around the world. The approval spurred investor interest and market projections, with experts predicting rapid patient adoption.

Clinical Trials 59

Clinical Trials Clinical Trials Marketing Research 59

Pharmaceutical Technology

AUGUST 4, 2022

The research and development (R&D) of various present and new ‘off-the-shelf’ cell therapies against targets in B-cell lymphomas, multiple myeloma and other hematologic indications are included in this alliance. Furthermore, Roche will oversee the late-stage clinical development and worldwide marketing of all products under the alliance.

Development 147

Development Clinical Trials Clinical Trials Gene Therapy 147

BioPharma Reporter

AUGUST 1, 2023

Renaissance Pharma, a company focused on the development of life changing therapies in pediatric rare disease, has entered into an exclusive license agreement with St. Jude Childrenâs Research Hospital for Hu14.18, a humanised antibody in development by the hospital for the treatment of newly diagnosed high-risk neuroblastoma.

Research 73

Research Licensing Licensing Antibody 73

Pharmaceutical Technology

MAY 31, 2023

C4 Therapeutics has entered an exclusive licensing agreement with Betta Pharmaceuticals to develop and commercialise CFT8919 across the greater China region. It is expected to accelerate the development of CFT8919 in important international markets.

In-Vivo 130

In-Vivo Bioavailability In-Vitro Licensing 130

BioPharma Reporter

DECEMBER 6, 2021

Australiaâs Noxopharm has in-licensed novel RNA tech developed by Hudson Institute of Medical Research: focusing on RNA drug discovery and mRNA vaccine manufacture via Noxopharmâs subsidiary Pharmorage.

RNA 52

RNA Licensing Licensing Vaccine 52

Pharmaceutical Technology

MARCH 28, 2023

Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D). Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Gene Editing 235

Gene Editing Gene DNA Gene Therapy 235

BioPharma Reporter

JUNE 1, 2021

Corbus Pharmaceuticals announced the expansion of its portfolio into immuno-oncology through licensing deals with the University of California San Francisco and Panorama Research Inc for two new monoclonal antibodies (mAbs).

Licensing 52

Licensing Licensing Antibody Research 52

XTalks

MAY 5, 2022

Based on the science from the researchers who established the framework of modern Paleolithic nutrition, the program aims to provide guidance for the food industry by codifying Paleo Diet standards and making them available to manufacturers, retailers and other partners. In the US alone, the Paleo market was estimated at $2.7

Packaging 98

Packaging Packaging Licensing Licensing 98

Fossil Remedies

AUGUST 31, 2022

The main thing is you should know the different aspects of costs while doing the research about a pharmaceutical company. Another important thing is company registration and DLN (Drug License Number). Minimum Investment to Start a Pharma Marketing Company. You need the promotional stuff and other things to market your products.

Pharma Companies 98

Pharma Companies Licensing Licensing Manufacturing 98

BioSpace

OCTOBER 12, 2021

Seattle-based Immusoft announced it had inked a research pact and license option deal with Takeda to create, develop, and market cell therapies in rare inherited metabolic diseases with CNS manifestations and complications.

Licensing 75

Licensing Licensing Marketing Development 75

Pharmaceutical Technology

FEBRUARY 17, 2023

Under the multiyear deal, Zephyr AI will license M2Gen’s RWD and will, in return, provide M2Gen will AI and machine learning technologies to enhance its products and services. It will use the machine learning platform from Zephyr AI and a real-world data set (RWD) from M2GEN for creating an oncology discovery product.

Bioinformatics 147

Bioinformatics Production Clinical Trials Clinical Trials 147

Roots Analysis

AUGUST 1, 2024

GLP-1 receptor agonist market have captured the attention of both large and small pharmaceutical companies, for more than a decade. GLP-1 Receptor Agonist Market – Current Landscape Presently, more than 150 GLP-1 drug candidates have been commercialized / being developed by more 55 developers to treat various metabolic disorders.

Marketing 52

Marketing Insulin Drugs Development 52

Pharmaceutical Technology

NOVEMBER 22, 2022

The US Food and Drug Administration (FDA) has accepted AbbVie ’s Biologics License Application (BLA) of epcoritamab (DuoBody-CD3xCD20) to treat adults with relapsed/refractory (r/r) large B-cell lymphoma (LBCL), for priority review. Epcoritamab is intended for usage in such patients following two or more lines of systemic therapy.

Clinical Trials 130

Clinical Trials Clinical Trials Licensing Licensing 130

Pharmaceutical Technology

MARCH 27, 2023

Iovance Bioterapeutics announced it has completed its rolling Biologics License Application (BLA) submission to the U.S. Marc Hurlbert, CEO of the Melanoma Research Alliance (MRA) said he hopes for a quick FDA approval. Iovance has a market cap of $1.2bn and recently acquired Proleukin from Clinigen for $206m in January 2023.

FDA Approval 130

FDA Approval Licensing Licensing Trials 130

Pharmaceutical Technology

OCTOBER 31, 2022

The European Medicines Agency (EMA) has validated AbbVie ’s marketing authorization application (MAA) for epcoritamab (DuoBody-CD3xCD20) to treat relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in adult patients following two or more lines of systemic therapy.

Antibody 130

Antibody Licensing Licensing Trials 130

Drug Channels

MARCH 18, 2025

Pharmacies and PBMs, Examining $683 Billion Market Review pricing/license options and download the full 2025 report Order before March 31, 2025 to receive special discounted pricing! WHATS GOING ON Twice a year, the DCI team researches and writes two comprehensive, fact-based, and nonpartisan reports on drug channel economics.

Pharmacy 52

Pharmacy Licensing Licensing Drugs 52

pharmaphorum

DECEMBER 16, 2020

AbbVie is to begin clinical development of an antibody designed to neutralise the SARS-CoV-2 coronavirus after licensing the therapy in from Harbour BioMed and Utrecht University. AbbVie will conduct clinical development of ABBV-47D11, and if successful, will manufacture and market the product worldwide.

Antibody 98

Antibody Trials Licensing Licensing 98

Pfizer

JANUARY 27, 2023

telehealth, in-person visit) with a physician, advanced practice registered nurse, or physician assistant licensed or authorized under state law to prescribe drugs, if any of the following apply: Sufficient information is not available to assess renal and hepatic function.

Marketing 75

Marketing Production Drugs Licensing 75